Conservative investors often seek out Dividends to support their Retire Fund investments. American and Canadian retirees like REIT's and especially Dividend payers!

Dividends are a great way to boost your RetireFund investments 

and REIT's often are in the mix of Dividend allstars.

Here are five American REITs that have strong dividend histories and are dividend all-stars:

1. Federal Realty Investment Trust (FRT):

   With at least 25 years of dividend hikes, FRT is a well-established REIT. It focuses on retail and mixed-use properties.

2. Universal Health Realty Income Trust (UHT): UHT also boasts over 25 years of consistent dividend increases. It primarily invests in healthcare and medical office buildings.

3. National Retail Properties (NNN): NNN has a long history of dividend growth. It specializes in single-tenant retail properties across the United States.

4. Realty Income (O): Known as the “Monthly Dividend Company,” Realty Income has consistently paid dividends for more than 50 years. It invests in retail and commercial properties.

5. Essex Property Trust (ESS): ESS focuses on multifamily residential properties and has maintained a strong dividend track record for over two decades1.

Always consult with a financial advisor if you’re unsure about specific investments

 

Here are five Canadian REITs that also pay solid dividends

1. Allied Properties REIT (AP-UN.TO): With a high dividend yield of 10.14%, Allied Properties focuses on urban office properties and has a market cap of approximately $2.17 billion.
2. CT REIT (CRT-UN.TO): This REIT is associated with Canadian Tire and offers a dividend yield of 7.7%. It has a market cap of around $503.30 million.
3. Dream Industrial Real Estate Investment Trust (DIR-UN.TO): Dream Industrial REIT primarily invests in industrial properties. Its dividend yield is 9.45%.
4. Choice Properties Real Estate Investment Trust (CHP-UN.TO): Choice Properties focuses on retail properties and has a dividend yield of 9.45%1.
5. Granite Real Estate Investment Trust (GRT-UN.TO): Granite REIT specializes in industrial and logistics properties. Its dividend yield stands at 7.7%.

Remember that investing involves risks, and it’s essential to conduct thorough research and consider your own financial goals before making any investment decisions.

 If you’re interested in a broader exposure to REITs, you can also explore REIT exchange-traded funds (ETFs) such as iShares S&P/TSX Capped REIT Index ETF (XRE.TO), BMO Equal Weight REITs Index ETF (ZRE.TO), and Vanguard FTSE Canadian Capped REIT Index ETF (VRE.TO). 

Happy investing!

D-Wave Quantum Inc., a leader in quantum computing systems, software, and services, has several notable advantages in the field of quantum technology.

  Let’s explore some of the reasons why D-wave Quantum Technology

is a leader and first mover in the field:

1. Quantum Annealing Technology:

   • D-Wave’s quantum computers use a process called quantum annealing. 
   • In nature, physical systems tend to evolve toward their lowest energy state. Quantum annealing leverages this behavior to search for solutions to complex problems.
   • Quantum annealing is particularly well-suited for combinatorial optimization problems with large numbers of variables and constraints. 
   • It can potentially address challenges in various domains, including materials science, drug discovery, and logistics.

2. Scalable Gate-Model Quantum Computing:

   • D-Wave is actively working on building and delivering a scalable gate-model quantum computing technology. Unlike annealing-based quantum computers, gate-model quantum computers allow for more general quantum computations.
   • This technology will unlock new capabilities in simulating quantum systems, with applications in areas such as materials science and drug discovery.

3. Energy Efficiency and Sustainability:

   • As artificial intelligence (AI) continues to advance, it consumes significant amounts of energy. Quantum computing offers a more scalable and energy-efficient solution for driving supercharged optimization.
   • By combining quantum computing with AI, organizations can make more precise predictions of supply and demand, optimize routing, production, and inventory management, and reduce costs and carbon emissions.

4. Real-World Applications:

   • D-Wave’s technology has been used by some of the world’s most advanced organizations, including Mastercard, Deloitte, Siemens Healthineers, and Lockheed Martin.
   • These organizations leverage D-Wave’s quantum computing systems to solve real-world problems across diverse domains, demonstrating the practical impact of quantum technology.

In summary, D-Wave Quantum’s edge lies in its quantum annealing technology, commitment to scalable gate-model quantum computing, energy efficiency, and successful applications in various fields.

 As quantum computing continues to evolve, D-Wave remains at the forefront of innovation. 

How Quantum annealing technology is being applied in various fields such as business, healthcare, and finance, leveraging its optimization capabilities to solve complex problems.

Pure plays in the race for Quantum Computing technology, IONQ, Quantinuum and D-wave technologies - comparisons!

Dwave on YouTube...

youtube.com/watch?v=P2hn9kQHi_s

Editas Medicine and CRISPR Therapeutics are both gene-editing companies that focus on developing therapies using CRISPR-Cas9 technology.

  Let’s explore their differences and where they stand in terms of DNA editing technology:

1. Editas Medicine:

   • Market Cap: Approximately $4 billion.
   • Gene Therapy Candidates:
     • EDIT-101: In phase 1 trials, targeting a hereditary retinal disorder that can cause blindness in infants.
     • EDIT-301: Under development to treat sickle cell disease (SCD) and beta thalassemia, both hereditary blood disorders.
   • Potential Impact:
     • EDIT-101 could address a condition affecting over 30,000 patients.
     • EDIT-301 targets SCD and beta thalassemia, conditions with a significant patient population.
   • Financial Position: Editas has about $500 million in cash on hand and raised additional funds to support its operations.

2. CRISPR Therapeutics:

• Market Cap: Approximately $5 billion.
• Gene Therapy Candidates:
  • CTX001: Already has data from clinical trials for treating beta thalassemia and sickle cell disease.
  • Oncology Pipeline: CRISPR is also specializing in immuno-oncology.
• Potential Impact:
  • CTX001 has shown promise in treating blood disorders.
  • The oncology pipeline expands CRISPR’s reach beyond rare genetic disorders.
• Financial Position: CRISPR is in a slightly better financial position than Editas.
3. CRISPR Therapeutics is further along in terms of clinical-stage development, with data on its key gene therapy candidate already available. Given its potential market reach and financial stability, CRISPR appears to be a safer choice for investors. 
4. However, in the long term, it’s challenging to predict which company will ultimately be the better stock. 
5. Both companies contribute to the exciting field of DNA editing technology, and their progress is closely watched by investors and researchers alike. 
6. Editas is now followed by a number of analysts including, Citigroup, Morgan Stanley and Barclays. These three have price targets between $9 and $15 per share at this writing!
7. While Editas Medicine and CRISPR Therapeutics are both prominent players in the field of gene editing technology. Let’s explore some of their competitors

8. 1. Verve Therapeutics: Based in Cambridge, Massachusetts, Verve Therapeutics focuses on revolutionizing cardiovascular disease treatment by moving away from long-term maintenance and single-course gene-editing therapies. Their initial research centers around PCSK9 and ANGPTL3, two genes that control blood lipid levels1.

   2. eGenesis: Also located in Cambridge, Massachusetts, eGenesis has developed a gene editing and genome engineering platform with the goal of transforming the treatment of critical diseases through solid organ and therapeutic cell transplantation.

   3. Bluebird Bio: While not directly competing with Editas and CRISPR Therapeutics, Bluebird Bio is a significant player in the gene editing field. They have already commercialized near-curative or curative therapies for sickle cell disease (SCD) and have a curative treatment for transfusion-dependent thalassemia (TDT) on the market2.

   4. Other Emerging Players: Beyond these specific companies, there are numerous other biotech firms and research institutions actively working on gene editing technologies. The landscape  dynamic, with ongoing advancements and collaborations driving innovation across various industries worldwide.

   Editas Medicine $EDIT has pioneered the use of CRISPR technology to develop innovative genomic medicines, potentially transforming the treatment of a wide range of genetic diseases

   "The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi

In Bio Science, there is a race for better Gene sequencing and genomics technology!

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology, focusing on harnessing the adaptive immune system for diagnosing and treating diseases

As Healthcare and Biotech companies utilize cutting edge Ai technology, more and more diseases will be conquered.

 Let’s take a look at the treatments offered by three, up and coming, BioTech companies with cutting edge therapies, that are currently on our watch list!

 (No positions at this writing):

1. Syndax Pharmaceuticals:

   • Axatilimab: An anti-CSF-1R monoclonal antibody. It’s being developed for chronic graft-versus-host disease (cGVHD) and other immune-mediated diseases where CSF-1R-dependent monocytes and macrophages contribute to organ fibrosis.
   • Revumenib: Received FDA Breakthrough Therapy Designation for treating adult and pediatric patients with relapsed or refractory KMT2A-rearranged MLLr acute leukemia.

2. Autolus Therapeutics:

   • Autolus is focused on developing next-generation programmed T-cell therapies for cancer. They have several clinical-stage candidates, including AUTO1, AUTO3, and AUTO4, which target different types of leukemia and lymphoma. These therapies are still in clinical trials.

3. Xencor Inc.:

   • Xencor is known for its XmAb antibody engineering platform. While they don’t have direct treatments, they collaborate with other companies to develop novel therapies using their technology
   • -----------------------------------------------------------------------------------------------------------------------------------------

In summary, Syndax Pharmaceuticals has made notable progress, while Autolus Therapeutics is primarily in clinical trials, and Xencor focuses on antibody engineering. 

As of today, Autolus Therapeutics and Syndax Pharmaceuticals have been in the spotlight, with analysts weighing in on their potential. Let’s take a closer look:

1. Autolus Therapeutics (AUTL):

   • Needham analyst Gil Blum maintains a Buy rating on Autolus Therapeutics, setting a price target of $9.00. The company’s shares closed last Friday at $4.501.
   • Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies.
   •  They recently announced the acceptance of a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel), which targets patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (B-ALL)2.

2. Syndax Pharmaceuticals (SNDX):

   • Syndax is advancing the next generation of targeted treatments for cancer. They focus on acute leukemias and chronic graft-versus-host disease.
   • Recently, Syndax reported its financial results for the first quarter of 2024 and provided a business update
   • 
     
   • There’s no specific information regarding any of the three being takeover targets at the moment. 
   • Keep an eye on news and analyst reports for any updates on these companies and remember, that, the big dogs of BioTech are always on the lookout for smaller companies with great new technology!

Agenus Inc. (formerly known as Agenus Therapeutics) is not claiming to be close to a cure for any form of cancer, but they are making significant strides in developing innovative cancer therapies.

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology, focusing on harnessing the adaptive immune system for diagnosing and treating diseases

Trapped ion technology has a lead in the race to bring quantum computing technology in to the main stream!

Which companies are taking advantage of IONQ'S quantum computing technology and how are they employing it at present?

Here are some key points that set IonQ apart from other competitors:

1. Trapped Ion Technology: IonQ focuses on trapped ion quantum computing, which is one of the most promising approaches. Trapped ions allow for better qubit stability and error correction, making IonQ’s systems robust and reliable.

2. High-Performance Systems: IonQ delivers high-performance quantum computers capable of solving complex commercial and research problems. Their systems are designed to tackle real-world challenges.

3. Industry-First Reconfigurable Multicore Architecture: 

    IonQ introduced an industry-first reconfigurable multicore quantum architecture. 

4. This

   innovation

   enables efficient use of qubits and flexibility in solving different types of problems.

5. Commercial and Research Use Cases: 

6. IonQ’s systems are used for both commercial and research purposes. They address a wide range of applications, from optimization and simulation to cryptography and material science.

7. IonQ's trapped ion computing, has achieved technical milestones ahead of schedule. 

8. Current customers include Airbus, Hyundai Motors, and the United States Air Force Research Laboratory

In summary, IonQ’s focus on trapped ion technology, high-performance systems, and innovative architecture positions them as

 a leader in the quantum computing landscape. 

IonQ’s approach has garnered significant attention and recognition in the field.

Here are five other companies working with trapped ion quantum computing technology:

1. Quantinuum: Formed in 2021 through a merger between Cambridge Quantum Computing (CQC) and Honeywell Quantum Solutions, Quantinuum aims to scale trapped ion quantum computing and address real-world challenges.
2. Quantum Factory: Founded in 2018 in Munich, Quantum Factory focuses on trapped ion technology and its applications.
3. Alpine Quantum Technologies: This company is also working on building quantum computers using trapped ions.
4. Oxford Ionics: Another player in the trapped ion space, Oxford Ionics is exploring the potential of this technology
5. EleQtron: While less known, EleQtron is actively involved in trapped ion quantum computing.

These competitors are also pushing the boundaries of what’s possible in quantum computing, with applications spanning AI, drug design, and cryptography. 

IONQ was founded by a team of leading experts in the field of quantum computing. The key figures behind IONQ include:

1. Chris Monroe: Chris Monroe is a co-founder of IONQ and a prominent physicist known for his research in quantum information science and trapped-ion quantum computing. He has been instrumental in developing IONQ's technology.

2. Jungsang Kim: Jungsang Kim is another co-founder of IONQ and a professor at Duke University. He has extensive experience in quantum information processing and has contributed significantly to the development of IONQ's trapped-ion quantum computing platform.

These individuals, along with their teams of researchers and engineers, have been pivotal in advancing IONQ's technology and positioning the company as a leader in the quantum computing industry.

The business partnerships that IONQ has in advancing trapped ion, quantum computing, are a who's who of business and Government and so is their list of investors

IONQ and Dwave quantum technologies could well be a drawing card for much larger companies to consider buying, Here's why!

Pure plays in the race for Quantum Computing technology, IONQ, Quantinuum and D-wave technologies - comparisons!

Interest in Quantum computing technology is growing. Should there be consolidation in the quantum space, one company stands out as a takeover target!